Source: http://www.google.com/patents/US20030166992?dq=6335678
Timestamp: 2017-04-29 20:10:30
Document Index: 536979367

Matched Legal Cases: ['art 14', 'art 14', 'art 14', 'art 14', 'art 14', 'art 14', 'art 14', 'art 14', 'art 14']

Patent US20030166992 - Heart wall tension reduction apparatus - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsAn apparatus for treatment of a failing heart by reducing the wall tension therein. In one embodiment, the apparatus includes a tension member for drawing at least two walls of a heart chamber toward each other....http://www.google.com/patents/US20030166992?utm_source=gb-gplus-sharePatent US20030166992 - Heart wall tension reduction apparatusAdvanced Patent SearchTry the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.Publication numberUS20030166992 A1Publication typeApplicationApplication numberUS 10/326,595Publication dateSep 4, 2003Filing dateDec 20, 2002Priority dateJan 2, 1997Also published asCA2275766A1, CA2275766C, DE69737955T2, EP1011461A1, EP1011461A4, EP1011461B1, US6050936, US6059715, US6162168, US6165119, US6165120, US6332863, US6332864, US6514194, US6589160, US6755777, US6793618, US7695425, US20020058855, US20020068849, US20020077524, US20030171641, US20040167374, US20090137863, WO1998029041A1Publication number10326595, 326595, US 2003/0166992 A1, US 2003/166992 A1, US 20030166992 A1, US 20030166992A1, US 2003166992 A1, US 2003166992A1, US-A1-20030166992, US-A1-2003166992, US2003/0166992A1, US2003/166992A1, US20030166992 A1, US20030166992A1, US2003166992 A1, US2003166992A1InventorsCyril Schweich, Todd MortierOriginal AssigneeMyocor, Inc.Export CitationBiBTeX, EndNote, RefManPatent Citations (10), Referenced by (73), Classifications (25), Legal Events (5) External Links: USPTO, USPTO Assignment, EspacenetHeart wall tension reduction apparatus
FIELD OF THE INVENTION [0001] The present invention pertains to the field of apparatus for treatment of a failing heart. In particular, the apparatus of the present invention is directed toward reducing the wall stress in the failing heart. BACKGROUND OF THE INVENTION [0002] The syndrome of heart failure is a common course for the progression of many forms of heart disease. Heart failure may be considered to be the condition in which an abnormality of cardiac function is responsible for the inability of the heart to pump blood at a rate commensurate with the requirements of the metabolizing tissues, or can do so only at an abnormally elevated filling pressure. There are many specific disease processes that can lead to heart failure with a resulting difference in pathophysiology of the failing heart, such as the dilatation of the left ventricular chamber. Etiologies that can lead to this form of failure include idiopathic cardiomyopathy, viral cardiomyopathy, and ischemic cardiomyopathy. [0003] The process of ventricular dilatation is generally the result of chronic volume overload or specific damage to the myocardium. In a normal heart that is exposed to long term increased cardiac output requirements, for example, that of an athlete, there is an adaptive process of slight ventricular dilation and muscle myocyte hypertrophy. In this way, the heart fully compensates for the increased cardiac output requirements. With damage to the myocardium or chronic volume overload, however, there are increased requirements put on the contracting myocardium to such a level that this compensated state is never achieved and the heart continues to dilate. [0004] The basic problem with a large dilated left ventricle is that there is a significant increase in wall tension and/or stress both during diastolic filling and during systolic contraction. In a normal heart, the adaptation of muscle hypertrophy (thickening) and ventricular dilatation maintain a fairly constant wall tension for systolic contraction. However, in a failing heart, the ongoing dilatation is greater than the hypertrophy and the result is a rising wall tension requirement for systolic contraction. This is felt to be an ongoing insult to the muscle myocyte resulting in further muscle damage. The increase in wall stress is also true for diastolic filling. Additionally, because of the lack of cardiac output, there is generally a rise in ventricular filling pressure from several physiologic mechanisms. Moreover, in diastole there is both a diameter increase and a pressure increase over normal, both contributing to higher wall stress levels. The increase in diastolic wall stress is felt to be the primary contributor to ongoing dilatation of the chamber. [0005] Prior art treatments for heart failure fall into three generally categories. The first being pharmacological, for example, diuretics. The second being assist systems, for example, pumps. Finally, surgical treatments have been experimented with, which are described in more detail below. [0006] With respect to pharmacological treatments, diuretics have been used to reduce the workload of the heart by reducing blood volume and preload. Clinically, preload is defined in several ways including left ventricular end diastolic pressure (LVEDP), or left ventricular end diastolic volume (LVEDV). Physiologically, the preferred definition is the length of stretch of the sarcomere at end diastole. Diuretics reduce extra cellular fluid which builds in congestive heart failure patients increasing preload conditions. Nitrates, arteriolar vasodilators, angiotensin converting enzyme inhibitors have been used to treat heart failure through the reduction of cardiac workload through the reduction of afterload. Afterload may be defined as the tension or stress required in the wall of the ventricle during ejection. Inotropes like digoxin are cardiac glycosides and function to increase cardiac output by increasing the force and speed of cardiac muscle contraction. These drug therapies offer some beneficial effects but do not stop the progression of the disease. [0007] Assist devices include mechanical pumps and electrical stimulators. Mechanical pumps reduce the load on the heart by performing all or part of the pumping function normally done by the heart. Currently, mechanical pumps are used to sustain the patient while a donor heart for transplantation becomes available for the patient. Electrical stimulation such as bi-ventricular pacing have been investigated for the treatment of patients with dilated cardiomyopathy. [0008] There are at least three surgical procedures for treatment of heart failure: 1) heart transplant; 2) dynamic cardiomyoplasty; and 3) the Batista partial left ventriculectomy. Heart transplantation has serious limitations including restricted availability of organs and adverse effects of immunosuppressive therapies required following heart transplantation. Cardiomyoplasty includes wrapping the heart with skeletal muscle and electrically stimulating the muscle to contract synchronously with the heart in order to help the pumping function of the heart. The Batista partial left ventriculectomy includes surgically remodeling the left ventricle by removing a segment of the muscular wall. This procedure reduces the diameter of the dilated heart, which in turn reduces the loading of the heart. However, this extremely invasive procedure reduces muscle mass of the heart. SUMMARY OF THE INVENTION [0009] The present invention pertains to a non-pharmacological, passive apparatus for the treatment of a failing heart. The device is configured to reduce the tension in the heart wall. It is believed to reverse, stop or slow the disease process of a failing heart as it reduces the energy consumption of the failing heart, decrease in isovolumetric contraction, increases sarcomere shortening during contraction and an increase in isotonic shortening in turn increases stroke volume. The device reduces wall tension during diastole (preload) and systole. [0010] In one embodiment, the apparatus includes a tension member for drawing at least two walls of the heart chamber toward each other to reduce the radius or area of the heart chamber in at least one cross sectional plane. The tension member has anchoring member disposed at opposite ends for engagement with the heart or chamber wall. [0011] In another embodiment, the apparatus includes a compression member for drawing at least two walls of a heart chamber toward each other. In one embodiment, the compression member includes a balloon. In another embodiment of the apparatus, a frame is provided for supporting the compression member. [0012] Yet another embodiment of the invention includes a clamp having two ends biased toward one another for drawing at least two walls of a heart chamber toward each other. The clamp includes at least two ends having atraumatic anchoring member disposed thereon for engagement with the heart or chamber wall. BRIEF DESCRIPTION OF THE DRAWINGS [0013] [0013]FIG. 1 is a transverse cross-section of the left and right ventricles of a human heart showing the placement of a splint in accordance with the present invention; [0014] [0014]FIG. 2 is a transverse cross-section of the left and right ventricles of a human heart showing the placement of a balloon device in accordance with the present invention; [0015] [0015]FIG. 3 is a transverse cross-section of the left and right ventricles of a human heart showing the placement of an external compression frame structure in accordance with the present invention; [0016] [0016]FIG. 4 is a transverse cross-section of the left and right ventricles of a human heart showing a clamp in accordance with the present invention; [0017] [0017]FIG. 5 is a transverse cross-section of the left and right ventricles of a human heart showing a three tension member version of the splint of FIG. 1; [0018] [0018]FIG. 6 is a transverse cross-section of the left and right ventricles of a human heart showing a four tension member version of the splint shown in FIG. 1; [0019] [0019]FIG. 7 is a vertical cross-section of the left ventricle and atrium, the left ventricle having scar tissue; [0020] [0020]FIG. 8 is a vertical cross-section of the heart of FIG. 7 showing the splint of FIG. 1 drawing the scar tissue toward the opposite wall of the left ventricle; [0021] [0021]FIG. 9 is a vertical cross-section of the left ventricle and atrium of a human heart showing a version of the splint of FIG. 1 having an elongate anchor bar; [0022] [0022]FIG. 10 is a side view of an undeployed hinged anchor member; [0023] [0023]FIG. 11 is a side view of a deployed hinged anchor member of FIG. 10; [0024] [0024]FIG. 12 is a cross-sectional view of an captured ball anchor member; [0025] [0025]FIG. 13 is a perspective view of a cross bar anchor member; [0026] [0026]FIG. 14 is a idealized cylindrical model of a left ventricle of a human heart; [0027] [0027]FIG. 15 is a splinted model of the left ventricle of FIG. 14; [0028] [0028]FIG. 16 is a transverse cross-sectional view of FIG. 15 showing various modeling parameters; [0029] [0029]FIG. 17 is a transverse cross-section of the splinted left ventricle of FIG. 15 showing a hypothetical force distribution; and [0030] [0030]FIG. 18 is a second transverse cross-sectional view of the model left ventricle of FIG. 15 showing a hypothetical force distribution. DETAILED DESCRIPTION OF THE INVENTION [0031] Referring now to the drawings wherein like reference numerals refer to like elements throughout the several views, FIG. 1 shows a transverse cross-section of a left ventricle 10 and a right ventricle 12 of a human heart 14. Extending through the left ventricle is a splint 16 including a tension member 18 and oppositely disposed anchors 20. Splint 16 as shown in FIG. 1 has been positioned to draw opposite walls of left ventricle 10 toward each other to reduce the “radius” of the left ventricular cross-section or the cross-sectional area thereof to reduce left ventricular wall stresses. It should be understood that although the splint 16 and the alternative devices disclosed herein are described in relation to the left ventricle of a human heart, these devices could also be used to reduce the radius or cross-sectional area of the other chambers of a human heart in transverse or vertical directions, or at an angle between the transverse and vertical. [0032] [0032]FIG. 2 discloses an alternate embodiment of the present invention, wherein a balloon 200 is deployed adjacent the left ventricle. The size and degree of inflation of the balloon can be varied to reduce the radius or cross-sectional area of left ventricle 10 of heart 14. [0033] [0033]FIG. 3 shows yet another alternative embodiment of the present invention deployed with respect to left ventricle 10 of human heart 14. Here a compression frame structure 300 is engaged with heart 14 at atraumatic anchor pads 310. A compression member 312 having an atraumatic surface 314 presses against a wall of left ventricle 10 to reduce the radius or cross-sectional area thereof. [0034] [0034]FIG. 4 is a transverse cross-sectional view of human heart 14 showing yet another embodiment of the present invention. In this case a clamp 400 having atraumatic anchor pads 410 biased toward each other is shown disposed on a wall of left ventricle 10. Here the radius or cross-sectional area of left ventricle 10 is reduced by clamping off the portion of the wall between pads 410. Pads 410 can be biased toward each other and/or can be held together by a locking device. [0035] Each of the various embodiments of the present invention disclosed in FIGS. 1-4 can be made from materials which can remain implanted in the human body indefinitely. Such biocompatible materials are well-known to those skilled in the art of clinical medical devices. [0036] [0036]FIG. 5 shows an alternate embodiment of the splint of FIG. 1 referred to in FIG. 5 by the numeral 116. The embodiment 116 shown in FIG. 5 includes three tension members 118 as opposed to a single tension member 18 as shown in FIG. 1. FIG. 6 shows yet another embodiment of the splint 216 having four tension members 218. It is anticipated that in some patients, the disease process of the failing heart may be so advanced that three, four or more tension members may be desirable to reduce the heart wall stresses more substantially than possible with a single tension member as shown in FIG. 1. [0037] [0037]FIG. 7 is a partial vertical cross-section of human heart 14 showing left ventricle 10 and left atrium 22. As shown in FIG. 7, heart 14 includes a region of scar tissue 24 associated with an aneurysm or ischemia. As shown in FIG. 7, the scar tissue 24 increases the radius or cross-sectional area of left ventricle 10 in the region affected by the scar tissue. Such an increase in the radius or cross-sectional area of the left ventricle will result in greater wall stresses on the walls of the left ventricle. [0038] [0038]FIG. 8 is a vertical cross-sectional view of the heart 14 as shown in FIG. 7, wherein a splint 16 has been placed to draw the scar tissue 24 toward an opposite wall of left ventricle 10. As a consequence of placing splint 16, the radius or cross-sectional area of the left ventricle affected by the scar tissue 24 is reduced. The reduction of this radius or cross-sectional area results in reduction in the wall stress in the left ventricular wall and thus improves heart pumping efficiency. [0039] [0039]FIG. 9 is a vertical cross-sectional view of left ventricle 10 and left atrium 22 of heart 14 in which a splint 16 has been placed. As shown in FIG. 9, splint 16 includes an alternative anchor 26. The anchor 26 is preferably an elongate member having a length as shown in FIG. 9 substantially greater than its width (not shown). Anchor bar 26 might be used to reduce the radius or cross-sectional area of the left ventricle in an instance where there is generalized enlargement of left ventricle 10 such as in idiopathic dilated cardiomyopathy. In such an instance, bar anchor 26 can distribute forces more widely than anchor 20. [0040] [0040]FIGS. 10 and 11 are side views of a hinged anchor 28 which could be substituted for anchors 20 in undeployed and deployed positions respectively. Anchor 28 as shown in FIG. 10 includes two legs similar to bar anchor 26. Hinged anchor 28 could include additional legs and the length of those legs could be varied to distribute the force over the surface of the heart wall. In addition there could be webbing between each of the legs to give anchor 28 an umbrella-like appearance. Preferably the webbing would be disposed on the surface of the legs which would be in contact with the heart wall. [0041] [0041]FIG. 12 is a cross-sectional view of a capture ball anchor 30. Capture ball anchor 30 can be used in place of anchor 20. Capture ball anchor 30 includes a disk portion 32 to distribute the force of the anchor on the heart wall, and a recess 34 for receiving a ball 36 affixed to an end of tension member 18. Disk 32 and recess 34 include a side groove which allows tension member 38 to be passed from an outside edge of disk 32 into recess 34. Ball 36 can then be advanced into recess 34 by drawing tension member 18 through an opening 38 in recess 34 opposite disk 32. [0042] [0042]FIG. 13 is a perspective view of a cross bar anchor 40. The cross bar anchor 40 can be used in place of anchors 20. The anchor 40 preferably includes a disk or pad portion 42 having a cross bar 44 extending over an opening 46 in pad 42. Tension member 18 can be extended through opening 46 and tied to cross bar 42 as shown. [0043] In use, the various embodiments of the present invention are placed in or adjacent the human heart to reduce the radius or cross-section area of at least one chamber of the heart. This is done to reduce wall stress or tension in the heart or chamber wall to slow, stop or reverse failure of the heart. In the case of the splint 16 shown in FIG. 1, a canula can be used to pierce both walls of the heart and one end of the splint can be advanced through the canula from one side of the heart to the opposite side where an anchor can be affixed or deployed. Likewise, an anchor is affixed or deployed at the opposite end of splint 16. [0044] [0044]FIG. 14 is a view of a cylinder or idealized heart chamber 48 which is used to illustrate the reduction of wall stress in a heart chamber as a result of deployment of the splint in accordance with the present invention. The model used herein and the calculations related to this model are intended merely to illustrate the mechanism by which wall stress is reduced in the heart chamber. No effort is made herein to quantify the actual reduction which would be realized in any particular in vivo application. [0045] [0045]FIG. 15 is a view of the idealized heart chamber 48 of FIG. 14 wherein the chamber has been splinted along its length L such that a “figure eight” cross-section has been formed along the length thereof. It should be noted that the perimeter of the circular transverse cross-section of the chamber in FIG. 14 is equal to the perimeter of the figure eight transverse cross-section of FIG. 15. For purposes of this model, opposite lobes of the figure in cross-section are assumed to be mirror images. [0046] [0046]FIG. 16 shows various parameters of the FIG. 8 cross-section of the splinted idealized heart chamber of FIG. 15. Where l is the length of the splint between opposite walls of the chamber, R2 is the radius of each lobe, θ is the angle between the two radii of one lobe which extends to opposite ends of the portion of the splint within chamber 48 and h is the height of the triangle formed by the two radii and the portion of the splint within the chamber 48 (R1 is the radius of the cylinder of FIG. 14). These various parameters are related as follows: h=R 2 COS(θ/2) l=2R 2 SIN(θ/2) R 2 =R 1π/(2π−θ) [0047] From these relationships, the area of the figure eight cross-section can be calculated by: A 2=2π(R 2)2(1−θ/2π)+hl [0048] Where chamber 48 is unsplinted as shown in FIG. 14 A1, the original cross-sectional area of the cylinder is equal to A2 where θ=180°, h=0 and l=2R2. Volume equals A2 times length L and circumferential wall tension equals pressure within the chamber times R2 times the length L of the chamber. [0049] Thus, for example, with an original cylindrical radius of four centimeters and a pressure within the chamber of 140 mm of mercury, the wall tension T in the walls of the cylinder is 104.4 newtons. When a 3.84 cm splint is placed as shown in FIGS. 15 and 16 such that l=3.84 cm, the wall tension T is 77.33 newtons. [0050] [0050]FIGS. 17 and 18 show a hypothetical distribution of wall tension T and pressure P for the figure eight cross-section. As θ goes from 180° to 0°, tension Ts in the splint goes from 0 to a 2T load where the chamber walls carry a T load. [0051] It will be understood that this disclosure, in many respects, is only illustrative. Changes may be made in details, particularly in matters of shape, size, material, and arrangement of parts without exceeding the scope of the invention. Accordingly, the scope of the invention is as defined in the language of the appended claims Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS3019790 *Jul 15, 1960Feb 6, 1962Militana Robert JCombination hemostat and intravenous needleUS3980066 *Mar 25, 1975Sep 14, 1976C.A.V. LimitedFuel injection pumping apparatusUS4300564 *Nov 1, 1979Nov 17, 1981Olympus Optical Co., Ltd.Forceps for extracting stones in the pelvis of a kidneyUS5300087 *Jan 26, 1993Apr 5, 1994Knoepfler Dennis JMultiple purpose forcepsUS5360444 *Dec 9, 1993Nov 1, 1994Kenji KusuharaOccluder supporter and a method of attachment thereofUS5417709 *Apr 12, 1994May 23, 1995Symbiosis CorporationEndoscopic instrument with end effectors forming suction and/or irrigation lumensUS6258021 *Oct 25, 1999Jul 10, 2001Peter J. WilkIntrapericardial assist methodUS6261222 *Feb 3, 2000Jul 17, 2001Myocor, Inc.Heart wall tension reduction apparatus and methodUS6629921 *Oct 27, 2000Oct 7, 2003Myocor, Inc.Heart wall tension reduction apparatus and methodUS6651671 *Oct 12, 1999Nov 25, 2003Heartport, Inc.Lens-invasive devices and methods for cardiac valve surgery* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS6723038Oct 6, 2000Apr 20, 2004Myocor, Inc.Methods and devices for improving mitral valve functionUS6755777Dec 20, 2002Jun 29, 2004Myocor, Inc.Heart wall tension reduction apparatus and methodUS6764510Jan 9, 2002Jul 20, 2004Myocor, Inc.Devices and methods for heart valve treatmentUS6793618Dec 20, 2002Sep 21, 2004Myocor, Inc.Heart wall tension reduction apparatusUS6808488May 2, 2002Oct 26, 2004Myocor, Inc.External stress reduction device and methodUS7316706Jun 14, 2004Jan 8, 2008Medtronic Vascular, Inc.Tensioning device, system, and method for treating mitral valve regurgitationUS7666224Jul 7, 2005Feb 23, 2010Edwards Lifesciences LlcDevices and methods for heart valve treatmentUS7678145Jul 1, 2005Mar 16, 2010Edwards Lifesciences LlcDevices and methods for heart valve treatmentUS7695425Feb 17, 2004Apr 13, 2010Edwards Lifesciences LlcHeart wall tension reduction apparatus and methodUS7722523Jul 9, 2002May 25, 2010Edwards Lifesciences LlcTransventricular implant tools and devicesUS7766812Apr 14, 2006Aug 3, 2010Edwards Lifesciences LlcMethods and devices for improving mitral valve functionUS7766816Jun 8, 2006Aug 3, 2010Chf Technologies, Inc.Method and apparatus for closing off a portion of a heart ventricleUS7883539Apr 23, 2002Feb 8, 2011Edwards Lifesciences LlcHeart wall tension reduction apparatus and methodUS7981020Jun 5, 2008Jul 19, 2011Edwards Lifesciences LlcTransventricular implant tools and devicesUS8070805Jan 25, 2010Dec 6, 2011Edwards Lifesciences LlcDevices and methods for heart valve treatmentUS8092363Sep 5, 2007Jan 10, 2012Mardil, Inc.Heart band with fillable chambers to modify heart valve functionUS8092367May 16, 2008Jan 10, 2012Mardil, Inc.Method for external stabilization of the base of the heartUS8128553Dec 12, 2006Mar 6, 2012Mardil, Inc.Method and apparatus for external stabilization of the heartUS8187323Oct 19, 2001May 29, 2012Edwards Lifesciences, LlcValve to myocardium tension members device and methodUS8226711Jul 1, 2005Jul 24, 2012Edwards Lifesciences, LlcValve to myocardium tension members device and methodUS8267852Jul 8, 2010Sep 18, 2012Edwards Lifesciences, LlcHeart wall tension reduction apparatus and methodUS8394008Jul 29, 2010Mar 12, 2013Bioventrix, Inc.Steerable lesion excluding heart implants for congestive heart failureUS8425402Jul 21, 2009Apr 23, 2013Bioventrix, Inc.Cardiac anchor structures, methods, and systems for treatment of congestive heart failure and other conditionsUS8449442Dec 20, 2007May 28, 2013Bioventrix, Inc.Method and device for percutaneous left ventricular reconstructionUS8460173Sep 11, 2012Jun 11, 2013Edwards Lifesciences, LlcHeart wall tension reduction apparatus and methodUS8465500Jan 19, 2006Jun 18, 2013Mayo Foundation For Medical Education And ResearchThorascopic heart valve repair method and apparatusUS8491455Oct 3, 2008Jul 23, 2013Bioventrix, Inc.Treating dysfunctional cardiac tissueUS8506474Aug 21, 2006Aug 13, 2013Bioventrix, Inc.Method and device for treating dysfunctional cardiac tissueUS8506624Dec 2, 2011Aug 13, 2013Edwards Lifesciences, LlcDevices and methods for heart valve treatmentUS8579798Jun 5, 2008Nov 12, 2013Edwards Lifesciences, LlcExternal cardiac stress reduction methodUS8636639Jan 24, 2012Jan 28, 2014Bioventrix, Inc.Signal transmitting and lesion excluding heart implants for pacing, defibrillating, and/or sensing of heart beatUS8758393Oct 20, 2008Jun 24, 2014Neochord, Inc.Minimally invasive repair of a valve leaflet in a beating heartUS8968175Jul 23, 2013Mar 3, 2015Bioventrix, Inc.Treating dysfunctional cardiac tissueUS8968338Feb 19, 2010Mar 3, 2015Mayo Foundation For Medical Education And ResearchThorascopic heart valve repair method and apparatusUS8979750Sep 30, 2012Mar 17, 2015Bioventrix, Inc.Trans-catheter ventricular reconstruction structures, methods, and systems for treatment of congestive heart failure and other conditionsUS8986189Jul 1, 2010Mar 24, 2015Bioventrix, Inc.Method and apparatus for closing off a portion of a heart ventricleUS9039594Jan 28, 2014May 26, 2015Bioventrix, Inc.Signal transmitting and lesion excluding heart implants for pacing, defibrillating, and/or sensing of heart beatUS9044221Dec 29, 2011Jun 2, 2015Neochord, Inc.Exchangeable system for minimally invasive beating heart repair of heart valve leafletsUS9044231Mar 11, 2013Jun 2, 2015Bioventrix, Inc.Steerable lesion excluding heart implants for congestive heart failureUS9095363Sep 30, 2012Aug 4, 2015Bioventrix, Inc.Remote pericardial hemostasis for ventricular access and reconstruction or other organ therapiesUS9119720May 20, 2013Sep 1, 2015Bioventrix, Inc.Method and device for percutaneous left ventricular reconstructionUS9173711Sep 30, 2012Nov 3, 2015Bioventrix, Inc.Cardiac implant migration inhibiting systemsUS9173712Sep 30, 2012Nov 3, 2015Bioventrix, Inc.Over-the-wire cardiac implant delivery system for treatment of CHF and other conditionsUS9192374Oct 20, 2008Nov 24, 2015Neochord, Inc.Minimally invasive repair of a valve leaflet in a beating heartUS9198757Jul 7, 2009Dec 1, 2015Edwards Lifesciences, LlcMethods and devices for improving mitral valve functionUS9211115May 21, 2007Dec 15, 2015Bioventrix, Inc.Location, time, and/or pressure determining devices, systems, and methods for deployment of lesion-excluding heart implants for treatment of cardiac heart failure and other disease statesUS9259319Aug 13, 2013Feb 16, 2016Bioventrix, Inc.Method and device for treating dysfunctional cardiac tissueUS9320513Mar 13, 2015Apr 26, 2016Bioventrix, Inc.Trans-catheter ventricular reconstruction structures, methods, and systems for treatment of congestive heart failure and other conditionsUS9364213May 21, 2013Jun 14, 2016Mayo Foundation For Medical Education And ResearchThorascopic heart valve repair methodUS9370425Oct 14, 2013Jun 21, 2016Mardil, Inc.Cardiac treatment system and methodUS9402722May 27, 2015Aug 2, 2016Bioventrix, Inc.Steerable lesion excluding heart implants for congestive heart failureUS9421101Oct 14, 2013Aug 23, 2016Mardil, Inc.Cardiac treatment systemUS9421102Oct 14, 2013Aug 23, 2016Mardil, Inc.Cardiac treatment system and methodUS9486206Mar 2, 2015Nov 8, 2016Bioventrix, Inc.Treating dysfunctional cardiac tissueUS9526618Aug 28, 2015Dec 27, 2016Bioventrix, Inc.Method and device for percutaneous left ventricular reconstructionUS20020077524 *Feb 14, 2002Jun 20, 2002Myocor, Inc.Heart wall tension reduction apparatusUS20020173694 *May 6, 2002Nov 21, 2002Myocor, Inc.Stress reduction apparatus and methodUS20030198919 *Apr 17, 2002Oct 23, 2003Henry HubnerProcess and apparatus for treating an exhaust stream from a dental operatoryUS20040260317 *Jun 14, 2004Dec 23, 2004Elliot BloomTensioning device, system, and method for treating mitral valve regurgitationUS20060089711 *Sep 22, 2005Apr 27, 2006Medtronic Vascular, Inc.Multifilament anchor for reducing a compass of a lumen or structure in mammalian bodyUS20070025009 *Jul 19, 2006Feb 1, 2007Fuji Photo Film Co., Ltd.Magnetic recorderUS20070049971 *Jun 8, 2006Mar 1, 2007Sing-Fatt ChinMethod and apparatus for closing off a portion of a heart ventricleUS20070066863 *Aug 31, 2006Mar 22, 2007Medtronic Vascular, Inc.Device for treating mitral valve regurgitationUS20070073274 *Aug 21, 2006Mar 29, 2007Sing-Fatt ChinMethod and device for treating dysfunctional cardiac tissueUS20070203391 *Feb 23, 2007Aug 30, 2007Medtronic Vascular, Inc.System for Treating Mitral Valve RegurgitationUS20070265658 *May 12, 2006Nov 15, 2007Aga Medical CorporationAnchoring and tethering systemUS20080097148 *Dec 20, 2007Apr 24, 2008Chf Technologies, Inc.Method and device for percutaneous left ventricular reconstructionUS20080294251 *May 21, 2007Nov 27, 2008Bioventrix (A Chf Technologies' Company)Location, time, and/or pressure determining devices, systems, and methods for deployment of lesion-excluding heart implants for treatment of cardiac heart failure and other disease statesUS20090093670 *Oct 3, 2008Apr 9, 2009Bioventrix (A Chf Technologies, Inc.)Treating Dysfunctional Cardiac TissueUS20100016655 *Jul 21, 2009Jan 21, 2010Bio Ventrix (a CHF Technologies, Inc.Cardiac Anchor Structures, Methods, and Systems for Treatment of Congestive Heart Failure and Other ConditionsUS20100268020 *Jul 1, 2010Oct 21, 2010Bioventrix (A Chf Technologies, Inc.)Method and Apparatus For Closing Off a Portion of a Heart VentricleUS20110160750 *Jul 29, 2010Jun 30, 2011BioVentrix (a CHF Technologies Company)Steerable Lesion Excluding Heart Implants For Congestive Heart FailureUSD717954Oct 14, 2013Nov 18, 2014Mardil, Inc.Heart treatment device* Cited by examinerClassifications U.S. Classification600/16International ClassificationA61F2/00, A61F2/02, A61M31/00, A61N1/362, A61B17/12, A61B19/00, A61B17/122, A61B17/00, A61B17/04Cooperative ClassificationY10S623/91, A61B2017/00243, A61B2017/0404, A61F2/2481, A61B17/00234, A61F2/2487, A61B2017/0417, A61B2017/0435, A61B2017/048, A61B2017/0461, A61B2017/0429, A61B17/1227, A61B2017/0496European ClassificationA61F2/24W4, A61B17/00ELegal EventsDateCodeEventDescriptionSep 5, 2007ASAssignmentOwner name: VENTURE LENDING & LEASING IV, INC., CALIFORNIAFree format text: SECURITY AGREEMMENT;ASSIGNOR:MYOCOR, INC.;REEL/FRAME:019805/0072Effective date: 20070820Owner name: VENTURE LENDING & LEASING IV, INC.,CALIFORNIAFree format text: SECURITY AGREEMMENT;ASSIGNOR:MYOCOR, INC.;REEL/FRAME:019805/0072Effective date: 20070820Mar 21, 2008FPAYFee paymentYear of fee payment: 4Feb 16, 2009ASAssignmentOwner name: EDWARDS LIFESCIENCES LLC, CALIFORNIAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MYOCOR, INC.;REEL/FRAME:022277/0011Effective date: 20081029Owner name: EDWARDS LIFESCIENCES LLC,CALIFORNIAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MYOCOR, INC.;REEL/FRAME:022277/0011Effective date: 20081029Mar 21, 2012FPAYFee paymentYear of fee payment: 8Feb 25, 2016FPAYFee paymentYear of fee payment: 12RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services